Sélectionnez votre langue
Ces publications sont classées par ordre chronologique décroissant.
SANTAL
Int Forum Allergy Rhinol. 2024 Aug 20. doi: 10.1002/alr.23433. PMID: 39162093
Interpretability of operative and pathological reports for radiotherapy planning of sinonasal carcinomas: An ancillary study of the GORTEC 2016-02 SANTAL trial
Labarre C, Carsuzaa F, Fieux M, Verillaud B, Moya Plana A, De Gabory L, Patron V, Ferrand FR, Thariat J
CisFRad (GORTEC 2015-02)
Radiother Oncol 2024 Aug:197:110329. doi: 10.1016/j.radonc.2024.110329. Epub 2024 May 19
Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial
Christian Borel, Xu-Shan Sun, Alexandre Coutte, Guillaume Bera, Christian Sire, Sylvie Zanetta, Marc Alfonsi, Guillaume Janoray, Thierry Chatellier, Muriel Garcia-Ramirez, Elisabeta Gherga, Yasser Hammoud, Mickaël Burgy, Nelly Etienne-Selloum, Adeline Pechery, Marie-Hélène Girard-Calais, Michel Velten, Jean-Pierre Pignon, Mathilde Wanneveich, Jean Bourhis
ELAN FIT
Lancet Healthy Longev. 2024 May 14:S2666-7568(24)00048-5. PMID: 38759667
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial
Joël Guigay 1, Hervé Le Caer 2, François-Régis Ferrand 3, Lionel Geoffrois 4, Esma Saada-Bouzid 5, Jérôme Fayette 6, Christian Sire 7, Didier Cupissol 8, Emmanuel Blot 9, Pierre Guillet 10, Julien Pavillet 11, Laurence Bozec 12, Olivier Capitain 13, Frédéric Rolland 14, Philippe Debourdeau 15, Yoann Pointreau 16, Claire Falandry 17, Stéphane Lopez 18, Alexandre Coutte 19, Thierry Chatellier 20, Pierre Dalloz 21, Cécile Ortholan 22, Cécile Michel 23, Benjamin Lacas 24, Nadir Cheurfa 24, Dominique Schwob 24, Jean Bourhis 25, Cécile Mertens 26, Anne Aupérin 24; ELAN Group including Gustave Roussy, Unicancer GERICO and H&N groups, and GORTEC
ELAN FIT ELAN UNFIT
Lancet Healthy Longev. 2024 Mar;5(3):e182-e193
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial
Joël Guigay, Cécile Ortholan, Damien Vansteene, Didier Cupissol, Caroline Even, Marie-Christine Kaminsky, Christian Sire, Emmanuel Blot, Philippe Debourdeau, Laurence Bozec, Esma Saada-Bouzid, Jérôme Fayette, Pierre Dalloz, Yoann Pointreau, Hervé Le Caer, Claire Falandry, Laurence Digue, Antoine Braccini, Stéphane Lopez, Pierre Guillet, Cécile Michel, Nadir Cheurfa, Dominique Schwob, Jean Bourhis, Cécile Mertens, Anne Aupérin; ELAN Group including Gustave Roussy, Unicancer GERICO and H&N groups and the GORTEC
Future Oncol. 2023 Jul 13. doi: 10.2217/fon-2023-0322. PMID: 37439181
Long-term results from a clinical study of xevinapant plus chemoradiotherapy in people with
high-risk
locally advanced squamous cell carcinoma of the head and neck: a plain language
summary
Publication PDF
Yungan Tao, Xu-Shan Sun, Yoann Pointreau, Christophe L Tourneau, Christian Sire, Kathrin Gollmer, Philippa Crompton, Jean Bourhis
PembroRad
Ann Oncol. 2023 Jan;34(1):101-110. doi: 10.1016/j.annonc.2022.10.006. Epub 2022 Oct 28.PMID: 36522816
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial
Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, Prevost JB, Modesto A, Lafond C, Tourani JM, Miroir J, Kaminsky MC, Coutte A, Liem X, Chautard E, Vauleon E, Drouet F, Ruffier A, Ramee JF, Waksi G, Péchery A, Wanneveich M, Guigay J, Aupérin A, Bourhis J
Stereopost Op
Clin Transl Radiat Oncol. 2022 Nov 14;38:169-174. doi: 10.1016/j.ctro.2022.11.007. eCollection 2023 Jan.PMID: 36466746
Postoperative SBRT in the treatment of early-stage oropharyngeal and oral cavity cancers with high-risk margins: A dosimetric comparison of volumetric modulated arc therapy with or without non-coplanar arcs and acute toxicity outcomes from the STEREOPOSTOP GORTEC 2017-03 phase 2 trial
Publication PDF
Julian Biau, Laura Lopez, Emilie Thivat, Mélanie Casile, Corinne Millardet, Nicolas Saroul, Nathalie Pham-Dang, Ioana Molnar, Jean Bourhis, Michel Lapeyre
TPExtreme
Lancet Oncol 2021
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
Guigay J, Auperin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R
Cliquer ici pour télécharger la version complète en format .pdf
REACH
European Journal of Cancer, Volume 141, December 2020, Pages 21-29
Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)
Yungan Tao, Anne Auperin, Xushan Sun, Christian Sire, Laurent Martin, Alexandre Coutte, Cedrik Lafond , Jessica Miroir , Xavier Liem , Frederic Rolland, Caroline Even , France Nguyen, Esma Saada, Aline Maillard, Natacha Colin-Batailhou, Juliette Thariat, Joel Guigay , Jean Bourhis
Cliquer ici pour télécharger la version complète en format .pdf
CisFRAD (GORTEC 2015-02)
Virtual 2020 ESMO Congress
Standard versus fractionated high dose cisplatin concomitant with radiotherapy in locally advanced head & neck squamous cell cancer (LA-HNSCC): Results of the GORTEC 2015-02 CisFRad randomized trial
Publication PDF
C. Borel, X. Sun, A. Coutte, G. Bera, S. Zanetta, M. Alfonsi, G. Janoray, T. Chatellier, M. Garcia-Ramirez, E. Gherga, Y.Hammoud, N. Etienne-Selloum, A. Pechery, M.H. Girard-Calais, M. Velten, J-P. Pignon, M. Wanneveich, J.Bourhis
DEBIO 1143
Lancet Oncol. 2020 Sep;21(9):1173-1187. doi: 10.1016/S1470-2045(20)30327-2. Epub 2020 Aug 3.
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Sun XS, Tao Y, Le Tourneau C, Pointreau Y, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Zubel A, Zanna C, Brienza S, Crompton P, Rouits E, Gollmer K, Szyldergemajn S, Bourhis J.
Cliquer ici pour télécharger la version complète en format .pdf
STEREO POSTOP
BMC Cancer. 2020 Aug 5;20(1):730. doi: 10.1186/s12885-020-07231-3.
A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial.
Biau J, Thivat E, Millardet C, Saroul N, Pham-Dang N, Molnar I, Pereira B, Durando X, Bourhis J, Lapeyre M.
TREMPLIN
Eur J Cancer. 2020 Jul;133:86-93. doi: 10.1016/j.ejca.2020.04.009. Epub 2020 May 23.
Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial.
Janoray G, Pointreau Y, Alfonsi M, Sire C, Geoffrois L, de Raucourt D, Bardet E, Calais MH, Garaud P, Calais G.
2004-01
Radiother Oncol. 2020 May 15;150:18-25. doi: 10.1016/j.radonc.2020.05.021. Online ahead of print.
Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.
Tao Y, Auperin A, Blanchard P, Alfonsi M, Sun XS, Rives M, Pointreau Y, Castelli J, Graff P, Wong Hee Kam S, Thariat J, Veresezan O, Heymann S, Renard-Oldrini S, Lafond C, Cornely A, Casiraghi O, Boisselier P, Lapeyre M, Biau J, Bourhis J.
Radiother Oncol. 2020 Mar 27;147:30-39. doi: 10.1016/j.radonc.2020.03.006
Proton therapy for head and neck squamous cell carcinomas: A review of the physical and clinical challenges
Arnaud Beddok, Anthony Vela, Valentin Calugaru, Thomas Tessonnier, Jiri Kubes, Pauline Dutheil, Anais Gerard, Marie Vidal, Farid Goudjil, Carmen Florescu, Emmanuel Kammerer, Karen Benezery, Joel Herault, Philip Poortmans, Jean Bourhis, Juliette Thariat, on behalf of the GORTEC, the 3 French proton centers
Cliquer ici pour télécharger la version complète en format .pdf
2017-01 REACH
Barcelona 2019 ESMO Congress - Poster
Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous cell carcinoma of the Head and Neck: Safety phase of the randomized phase III trial GORTEC 2017-01 REACH
Publication PDF
Y Tao, A Auperin, X Sun, C Sire, L Martin, A Coutte, C Lafond, J Miroir, X Liem, F Rolland, A Maillard, N Colin-Barailhou, C Michel, J Thariat, J Guigay, J Bourhis
Front Oncol. 2019 May 31;9:419. doi: 10.3389/fonc.2019.00419. eCollection 2019.
Laryngeal Preservation Strategies in Locally Advanced Laryngeal and Hypopharyngeal Cancers.
Argiris A, Lefebvre JL.
Curr Opin Oncol. 2019 May;31(3):152-159. doi: 10.1097/CCO.0000000000000526.
Treatment of inoperable elderly head and neck cancer patients.
Guigay J, Le Caer H, Ortholan C, Aupérin A, Michel C, Mertens C.Guigay J, Le Caer H, Ortholan C, Aupérin A, Michel C, Mertens C.
Cancer Radiother. 2019 Sep;23(5):439-448. doi: 10.1016/j.canrad.2019.05.015. Epub 2019 Jul 26.
Proton therapy for head and neck squamous cell carcinomas : From physics to clinic
Beddok A, Vela A, Calugaru V, Tessonnier T, Kubes J, Dutheil P, Gérard A, Vidal M, Goudjil F, Florescu C, Kammerer E, Bénézery K, Hérault J, Bourhis J, Thariat J; Gortec et de trois centres français.
Radiother Oncol. 2019 Feb
Practical clinical guidelines for contouring the trigeminal nerve (V) and its branches in head and neck cancers.
Biau J, Dunet V, Lapeyre M, Simon C, Ozsahin M, Grégoire V, Bourhis J.
Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux (2007-01)
Publication PDF
Essai randomisé multicentrique de phase III évaluant l'apport d'une chimiothérapie concomitante chez les patients traités par radiothérapie - Erbitux pour un carcinome localement évolué des VADS <= N2a.
Coordinateur : Pr BOURHIS
Date de début : 2008
Nb Patients 406
Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux. (2007/02)
Etude de phase III randomisée, multicentrique comparant une chimiothérapie d'induction par TPF suivie d'une association radiothérapie Erbitux® versus une radiochimiothérapie concomitante chez des patients présentant un carcinome épidermoïde des VADS localement évolué inopérable >=N2b
Coordinateur : Dr GEOFFROIS
Date de début : 2009
Nb Patients 360
J Clin Oncol. 2018 Jul 17
Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial.
Geoffrois L, Martin L, De Raucourt D, Sun XS, Tao Y, Maingon P, Buffet J, Pointreau Y, Sire C, Tuchais C, Babin E, Coutte A, Rolland F, Kaminsky MC, Alfonsi M, Lapeyre M, Saliou M, Lafond C, Jadaud E, Gery B, Zawadi A, Tourani JM, Khoury C, Henry AR, Hasbini A, Guichard F, Borel C, Meert N, Guillet P, Calais MH, Garaud P, Bourhis J.
J Clin Oncol. 2018 Jun 7
Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.
Tao Y, Auperin A, Sire C, Martin L, Khoury C, Maingon P, Bardet E, Kaminsky MC, Lapeyre M, Chatellier T, Alfonsi M, Pointreau Y, Jadaud E, Géry B, Zawadi A, Tourani JM, Laguerre B, Coutte A, Racadot S, Hasbini A, Malaurie E, Borel C, Meert N, Cornely A, Ollivier N, Casiraghi O, Sun XS, Bourhis J.
Future Oncol. 2018 Apr
Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC.
Sun XS, Michel C, Babin E, De Raucourt D, Péchery A, Gherga E, Géry B, Florescu C, Bourhis J, Thariat J.
Int J Radiat Oncol Biol Phys. 2017 Nov 1
Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie Radiotherapie Tete et Cou) 2009-01 Evaluating the Effect of the Regenerating Agent on Radiodermatitis of Head and Neck Cancer Patients.
Tao Y, Auperin A, Sire C, Martin M, Saliou MG, Bardet E, Sun XS, Chatellier T, Morand C, Cornely A, Angokai M, Di Rito A, Kichenin K, Blanchard P, D'Onofrio I, Bourhis J.
Ann Oncol. 2018 Mar 1
A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02).
Frikha M, Auperin A, Tao Y, Elloumi F, Toumi N, Blanchard P, Lang P, Sun S, Racadot S, Thariat J, Alfonsi M, Tuchais C, Cornely A, Moussa A, Guigay J, Daoud J, Bourhis J; GORTEC.
Radiother Oncol. 2018 Jan
Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines.
Grégoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, Eisbruch A, Feng M, Giralt J, Gupta T, Hamoir M, Helito JK, Hu C, Hunter K, Johansen J, Kaanders J, Laskar SG, Lee A, Maingon P, Mäkitie A, Micciche' F, Nicolai P, O'Sullivan B, Poitevin A, Porceddu S, Składowski K, Tribius S, Waldron J, Wee J, Yao M, Yom SS, Zimmermann F, Grau C.
Cancer Radiother. 2017 Oct
[Description of the GORTEC 2017-03 study: Postoperative stereotactic radiotherapy for early stage oropharyngeal and oral cavity cancer with high risk margin (PHRC-K-16-164)].
Biau J, Miroir J, Millardet C, Saroul N, Pham-Dang N, Racadot S, Huguet F, Kwiatkowski F, Pereira B, Bourhis J, Lapeyre M.
Oral Oncol. 2017 Aug
Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
Tao Y, Aupérin A, Graff P, Lapeyre M, Grégoire V, Maingon P, Geoffrois L, Verrelle P, Calais G, Gery B, Martin L, Alfonsi M, Deprez P, Bardet E, Pignon T, Rives M, Sire C, Bourhis J.
Oral Oncol. 2017 May
Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEx) as first-line treatment followed by cetuximab maintenance.
Guigay J, Even C, Mayache-Badis L, Debbah M, Saada-Bouzid E, Tao Y, Deschamps F, Janot F, Lezghed N, Michel C.
Radiother Oncol. 2015 Oct
CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines.
Brouwer CL, Steenbakkers RJ, Bourhis J, Budach W, Grau C, Grégoire V, van Herk M, Lee A, Maingon P, Nutting C, O'Sullivan B, Porceddu SV, Rosenthal DI, Sijtsema NM, Langendijk JA.
Ann Oncol. 2015 Sep
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.
Guigay J, Fayette J, Dillies AF, Sire C, Kerger JN, Tennevet I, Machiels JP, Zanetta S, Pointreau Y, Bozec Le Moal L, Henry S, Schilf A, Bourhis J.
Bull Cancer. 2014 May 1
[Quality criteria in radiotherapy for head and neck cancers under the aegis of Head and Neck Intergroup].
Tao Y, Vintonenko N, Garcia R, Marchesi V, Tomsej M, Bardet E, Bourhis J.
Bull Cancer. 2013 Oct
[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC].
Thariat J, Jegoux F, Pointreau Y, Fayette J, Boisselier P, Blanchard P, Alfonsi M, Aupérin A, Bardet E, Bensadoun RJ, Garaud P, Geoffrois L, Graff P, Guigay J, Janot F, Lapeyre M, Lefebvre JL, Martin L, Racadot S, Rolland F, Sire C, Tao Y, Tuchais C, Chibaudel B, Girard-Calais MH, Cornely A, Vintonenko N, Calais G, De Raucourt D, Lacau Saint-Guily J, Bourhis J.
J Clin Oncol. 2013 Mar
Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study.
Lefebvre JL1, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Malard O, Degardin M, Tuchais C, Blot E, Rives M, Reyt E, Tourani JM, Geoffrois L, Peyrade F, Guichard F, Chevalier D, Babin E, Lang P, Janot F, Calais G, Garaud P, Bardet E.
Radiat Oncol. 2013 Feb
Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004-02
Tao Y, Bardet E, Rosine D, Rolland F, Bompas E, Daly-Schveitzer N, Lusinchi A, Bourhis J.
Radiother Oncol. 2012 Apr
Intensity-modulated radiotherapy in head and neck cancer: results of the prospective study GORTEC 2004-03.
Toledano I, Graff P, Serre A, Boisselier P, Bensadoun RJ, Ortholan C, Pommier P, Racadot S, Calais G, Alfonsi M, Favrel V, Giraud P, Lapeyre M.
Lancet Oncol. 2012 Apr
Absent benefit of accelerated concomitant chemoradiotherapy (GORTEC 99-02)
Bourhis J, Tao YG, Blanchard P, Sire C, Aupérin A .
The Lancet Oncology. 2012 Feb
Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial
Prof Jean Bourhis, Christian Sire, Pierre Graff, Prof Vincent Grégoire,Prof Philippe Maingon,Prof Gilles Calais, Bernard Gery, Laurent Martin, Marc Alfonsi, Patrick Desprez, Thierry Pignon, Etienne Bardet, Michel Rives, Lionel Geoffrois, Prof Nicolas Daly-Schveitzer, Sok Sen, Claude Tuchais, Olivier Dupuis, Stéphane Guerif, Michel Lapeyre, Véronique Favrel, Prof Marc Hamoir, Antoine Lusinchi, Stéphane Temam, Antonella Pinna, BScYun Gan Tao, Pierre Blanchard, Anne Aupérin
Radiother Oncol. 2011 Jul
Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial.
Bourhis J, Lapeyre M, Tortochaux J, Lusinchi A, Etessami A, Ducourtieux M, Geoffrois L, Domenge C, Verrelle P, Wibault P, Janot F, Temam S, Blanchard P, Tao YG, Auperin A. Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
Cliquer ici pour télécharger la version complète en format .pdf
Radiother Oncol. 2011 Jul
Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent.
Tortochaux J, Tao Y, Tournay E, Lapeyre M, Lesaunier F, Bardet E, Janot F, Lusinchi A, Benhamou E, Bontemps P, Maingon P, Calais G, Daly-Schveitzer N, Verrelle P, Bourhis J.
Cliquer ici pour télécharger la version complète en format .pdf
Radiother Oncol. 2011 Jan
A phase I trial combining oral cisplatin (CP Ethypharm) with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma.
Tao Y, Rezaï K, Brain E, Etessami A, Lusinchi A, Temam S, Urien S, Van ML, Vauzelle-Kervroedan F, Lokiec F, Daly-Schveitzer N, Bourhis J.
J Clin Oncol. 2010 Nov 29
Subcutaneous Compared With Intravenous Administration of Amifostine in Patients With Head and Neck Cancer Receiving Radiotherapy: Final Results of the GORTEC 2000-02 Phase III Randomized Trial.
Bardet E, Martin L, Calais G, Alfonsi M, Feham NE, Tuchais C, Boisselier P, Dessard-Diana B, Seng SH, Garaud P, Aupérin A, Bourhis J.
J Clin Oncol. - 2010 Jan 1
Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.
Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, Schmitz S, Bompas E, Dillies AF, Faivre S, Moxhon A, Duprez T, Guigay J.
Medical Oncology Unit, Université Catholique de Louvain, Cliniques Universitaires Saint-Luc
Int J Radiat Oncol Biol Phys. - 2009 Apr 20
TPF : a rational choice for larynx preservation ?
Calais G.
Concomitant Chemoradiotherapy Using Carboplatin, Tegafur-Uracil and Leucovorin for Stage III and IV Head-and-Neck Cancer: Results of GORTEC Phase II Study.
Fesneau M, Pointreau Y, Chapet S, Martin L, Pommier P, Alfonsi M, Laguerre B, Feham N, Berger C, Garaud P, Calais G.
Department of Radiation Oncology, Henry Kaplan Center, Tours, France.
Larynx preservation clinical trial design: key issues and recommendations--a consensus panel summary.
Ang K, Bardet E, Barry B, Bernier J, Bourhis J, Budach V, Calais G, Conley B, Forastiere A, Knecht R, Langendijk J, Lefebvre JL, Leemans R, Licitra L, Posner M, de Raucourt D, Rolland F, Temam S, Vermorken JB, Vokes E, Weber RS, Wolf G.
Département de Cancérologie Cervico-Faciale, Centre Oscar Lambret, Lille, France
J Natl Cancer Inst. 2009 Apr 1
Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G.
J Clin Oncol - 2008 Dec 1
Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.
Janot F, de Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensadoun RJ, Hamoir M, Géry B, Julieron M, Castaing M, Bardet E, Grégoire V, Bourhis J.
Institut Gustave-Roussy, 39 rue Camille Desmoulins, Villejuif, France
Rev Prat. - 2006 Oct 15
J Clin Oncol. - 2006 Jun 20
Phase III randomized trial of very accelerated radiation therapy compared with conventional
radiation
therapy in squamous cell head and neck cancer: a GORTEC trial
Bourhis J, Lapeyre M,
Tortochaux J, Rives M, Aghili M, Bourdin S, Lesaunier F, Benassi T, Lemanski C, Geoffrois L, Lusinchi A,
Verrelle P, Bardet E, Julieron M, Wibault P, Luboinski M, Benhamou E.
Institut Gustave Roussy,
Radiation
Oncology, Head and Neck Statistics Department, Villejuif, France
Int J Radiat Oncol Biol Phys. - 2006 Mar 15
French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC).
Bensadoun RJ, Bénézery K, Dassonville O, Magné N, Poissonnet G, Ramaïoli A, Lemanski C, Bourdin S, Tortochaux J, Peyrade F, Marcy PY, Chamorey E, Vallicioni J, Seng H, Alzieu C, Géry B, Chauvel P, Schneider M, Santini J, Demard F, Calais G.
Department of Radiation Oncology, Centre Antoine Lacassagne, Nice, France
Cancer Radiother. - 2005 Jun
Propositions for the selection and the delineation of peritumoral microscopic disease volumes in oral cavity and oropharyngeal cancers (lymph nodes excluded)
Bensadoun RJ, Bénézery K, Dassonville O, Magné N, Poissonnet G, Ramaïoli A, Lemanski C, Bourdin S, Tortochaux J, Peyrade F, Marcy PY, Chamorey E, Vallicioni J, Seng H, Alzieu C, Géry B, Chauvel P, Schneider M, Santini J, Demard F, Calais G., GORTEC
Département de radiothérapie, centre Alexis-Vautrin, avenue de Bourgogne, 54511 Vandoeuvre-Lès-Nancy, France
Cancer Radiother. - 2005 Feb
Larynx preservation, state of the art
Lefebvre JL, Calais G.
Département de cancérologie cervicofaciale, centre Oscar-Lambret, 3, rue Combemale, 59020 Lille cedex, France.
Cancer Radiother. 2005 Jun;9(4):261-70. Epub 2005 Apr 25.
Propositions for the selection and the delineation of peritumoral microscopic disease volumes in oral cavity and oropharyngeal cancers (lymph nodes excluded)
Lapeyre M, Henrot P, Alfonsi M, Bardet E, Bensadoun RJ, Dolivet G, Favrel V, Gallocher O, Giraud P, Graff P, Guerif S, Lagarde P, Lartigau E, Marchesi V, Pommier P, Rives M, Tortochaux J, Toussaint B, Verrelle P, Bourhis J, Calais G; Groupe Oncologie Radiothérapie Tête et Cou.
Département de radiothérapie, centre Alexis-Vautrin, avenue de Bourgogne, 54511 Vandoeuvre-Lès-Nancy, France. m.lapeyre[@]nancy.fnclcc.fr
Semin Oncol. - 2004 Dec
Concomitant radiochemotherapy or accelerated radiotherapy: analysis of two randomized trials of the French Head and Neck Cancer Group (GORTEC).
Bourhis J, Calais G, Lapeyre M, Tortochaux J, Alfonsi M, Sire C, Bardet E, Rives M, Bergerot P, Rhein B, Desprez B; French Head and Neck Cancer Group (GORTEC).
Department of Radiation-Oncology, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94805 Villejuif, France.
Curr Opin Oncol. - 2004 May
Altered fractionated radiotherapy in the management of head and neck carcinomas: advantages and limitations.
Bourhis J, Etessami A, Wilbault P, Lusinchi A, Calais G, Lapeyre M, Pignon JP.
Institut Gustave Roussy, Radiation Oncology & Statistic Departments, Villejuif, France.
Bull Cancer. - 2004 Feb
Docetaxel and squamous cell carcinoma of the head and neck
Calais G.
Clinique d'oncologie et radiothérapie, Hôpital Bretonneau, 2, bd Tonnellé, 37044 Tours.
Int J Radiat Oncol Biol Phys. - 2004 Jan 1
Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial.
Calais G, Bardet E, Sire C, Alfonsi M, Bourhis J, Rhein B, Tortochaux J, Man YT, Auvray H, Garaud P.
Centre Hospitalier Universitaire, Tours, France
J Clin Oncol. - 2004 Jan 1
Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.
Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G.
Clinique d'Oncologie et Radiothérapie, Hôpital Bretonneau, 2 Blvd Tonnelé, 37044 Tours, France
Radiother Oncol - 2003 Dec
FCT-based delineation of lymp node levels and related CTVs in the node-negative neck : DAHANCA, EORTC, GORTEC, NCIC, RTOG concensus guidelines
Grégoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, Chao C, Coche E, Cooper JS, Cosnard G, Eisbruch A, El-Sayed S, Emami B, Grau C, Hamoir M, Lee N, Maingon P, Muller K, Reychler H.
Radiation Oncology Dept. and Laboratory of Radiobiology, Université Catholique de Louvain, St-Luc University Hospital, B-1200 Brussels, Belgium.
Radiother Oncol - 2003 Dec
FLate toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage orophraynx carcinoma : comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems.
Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Calais G.
Clinique d'Oncologie et de Radiothérapie, Centre Hospitalier Universitaire, Tours, France
Radiother Oncol - 2003 Dec
FLate toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage orophraynx carcinoma : comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems.
Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Calais G.
Clinique d'Oncologie et de Radiothérapie, Centre Hospitalier Universitaire, Tours, France
Semin Oncol. - 2002 Dec
Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Bardet E, Martin L, Calais G, Tuchais C, Bourhis J, Rhein B, Feham N, Alphonsi M.
CRLCC Nantes Atlantique, Nantes, France.
Bull Cancer. - 2000 Aug
Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy
Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P.
Clinique d'oncologie et radiothérapie, Hôpital Bretonneau, Tours
J Natl Cancer Inst. - 1999 Dec 15
Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.
Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P.
G. Calais, Centre Hospitalier Universitaire Tours, France